Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. HIV infection is associated with type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. De novo electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HIV infection is associated with thoracic and abdominal aortic aneurysms: a prospective matched cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mark Jason Nelson
  • Gerardo Amaya
  • Nathan Clumeck
  • Clovis Arns da Cunha
  • Dushyantha Jayaweera
  • Patrice Junod
  • Taisheng Li
  • Pablo Tebas
  • Marita Stevens
  • Annemie Buelens
  • Simon Vanveggel
  • Katia Boven
  • ECHO and THRIVE Study Groups
  • Jan Gerstoft
Vis graf over relationer
The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.
OriginalsprogEngelsk
TidsskriftJournal of Antimicrobial Chemotherapy
Vol/bind67
Udgave nummer8
Sider (fra-til)2020-8
Antal sider9
ISSN0305-7453
DOI
StatusUdgivet - 2012

ID: 36459049